Engineered immune cells take aim at Hard-to-Treat KRAS cancers
NCT ID NCT07342738
First seen Jan 15, 2026 · Last updated May 16, 2026 · Updated 14 times
Summary
This early-phase study tests a personalized cell therapy called TCR-T in 25 adults with advanced solid tumors (like colorectal or lung cancer) that have specific KRAS mutations and haven't responded to standard treatments. The therapy uses the patient's own immune cells, engineered to recognize and attack cancer cells carrying the KRAS mutation. The main goals are to check safety and see if the treatment can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMOR are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.